BioCentury
ARTICLE | Company News

Epirus nabs biosimilars in Bioceros takeout

September 10, 2015 1:19 AM UTC

Epirus Biopharmaceuticals Inc. (NASDAQ:EPRS) acquired biosimilars company Bioceros B.V. (Utrecht, the Netherlands) for $14.1 million in cash and stock to be paid over a one-year period.

Epirus gains three preclinical candidates: BOW080, a biosimilar of Soliris eculizumab; BOW090, a biosimilar of Stelara ustekinumab; and BOW100, a biosimilar of Simponi golimumab. ...